vimarsana.com

Latest Breaking News On - Dawn biopharma - Page 1 : vimarsana.com

Adcendo ApS Announces Extension of Series A Financing to EUR 98M to Further Bolster its First-in-Class ADC Pipeline

Raises additional 16M EUR led by Dawn Biopharma, a platform controlled by KKR, with participation from existing investors.Funds will be used to further strengthen growing pipeline of first in

Iyona rajkomarMichael pehlHealthcare strategic growth fundNovo holdingsDawn biopharmaManaging partnerAdcendo boardYsios capitalGilde healthcarePontifax ventureDevelopment candidate nominationChief executive officerBoard directorPontifax venture capitalStrategic growth fundIhr portfolio

Adcendo Raises €16M; Extends Series A to €98M

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Michael pehlIyona rajkomarNovo holdingsDawn biopharmaYsios capitalGilde healthcarePontifax ventureManaging partnerAdcendo board

Agomab Therapeutics NV: Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline

Agomab Therapeutics NV: Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Colleen cuffaroTim knotnerusFelice verduyn van weegenIyona rajkomarFidelity management research companyTrophic communicationsLife sciencesDawn biopharmaFibrostenosing crohnIdiopathic pulmonary fibrosisFelice verduynChief executive officerAgomab therapeuticsStephanie mayAktien sie

Belgian biotech company Agomab Therapeutics raises €94 9M to tackle fibrosis; here s how

Ghent, Belgium-based Agomab Therapeutics, a biotech company, announced on Wednesday that it has closed a $100M (approximately €94.9M).

Felice verduyn van weegenColleen cuffaroIyona rajkomarTim knotnerusFidelity management research companyLife sciencesBelgium based agomab therapeuticsFidelity managementResearch companyDawn biopharmaFibrostenosing crohnAgomab therapeuticsIdiopathic pulmonary fibrosisAdvancing fibrosis focusedChief executive officer

Agomab Raises $100M in Series C Funding

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Tim knotnerusFidelity management research companyLife sciencesFidelity managementResearch companyDawn biopharmaFibrostenosing crohn

vimarsana © 2020. All Rights Reserved.